DCP
CGON icon

Davern Capital Partners’s CG Oncology CGON Stock Holding History

Davern Capital Partners’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-162,005
Closed -$6.73M – 18
2025
Q4 		$6.73M Buy
+162,005
New +$6.7M 2.17% 13

Other funds holding CGON

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Davern Capital Partners's CGON Position: Q1 2026 in Review

Davern Capital Partners sold out of CG Oncology (CGON) in Q1 2026, closing a stake of 162,005 shares — an estimated $6.73M sold.

Davern Capital Partners first reported a position in CGON in Q4 2025 and held it in 1 quarter. The position peaked at $6.73M in Q4 2025. 233 funds tracked by Wall St. Rank hold CGON as of Q1 2026.

  • Davern Capital Partners reported no remaining CG Oncology position as of Q1 2026 after selling out during the quarter.
  • Davern Capital Partners sold 162,005 CG Oncology shares in Q1 2026, an estimated $6.73M.
  • Davern Capital Partners first reported a position in CG Oncology in Q4 2025 and held it in 1 quarter.
  • Davern Capital Partners's CG Oncology position peaked at $6.73M in Q4 2025.
  • 233 funds tracked by Wall St. Rank held CG Oncology as of Q1 2026.

Based on Davern Capital Partners's 13F filing for Q1 2026, filed 14 May 2026.